Bristol-Myers says hepatitis C drug combination succeeds in study

April 25, 2015 9:04 PM

7 0

(Reuters) - Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc's Sovaldi and a commonly prescribed drug, ribavirin, in a late-stage study.

Data presented at the International Liver Congress on Saturday showed that the combination cured 94 percent of the patients suffering from hepatitis C after a liver transplant and 83 percent of patients with severe scarring.

Read more

To category page